For-profit drug manufacturers want to change how the 340B Drug Pricing Program works, but going from upfront savings to back-end rebates will kill nonprofit health providers.

Congress is considering a new bill that, in theory, would boost low-income patients’ - especially Latinos’ - access to ...

The hospital lobby wants the Trump administration to investigate Johnson & Johnson, Eli Lilly, Sanofi, Novartis and Bristol ...

A group of House lawmakers is urging HHS to scrap or revise its proposed 340B rebate model pilot program, warning the model could dismantle the original intent of the program and harm safety-net ...

More than 160 lawmakers have urged the Trump administration to abandon a newly announced pilot program that would allow ...

HRSA is piloting a 340B rebate model similar to one that it just fought against. As the agency dips its toes into the 340B debate, hospital groups express concerns about the potential for cash flow ...

The pilot is a significant departure from the current model, which gives hospitals upfront discounts for some drugs. The program has proved a flash point between drugmakers and providers, as ...

The pharmaceuticals lobby shored up its campaign against increasing use of the 340B Drug Discount Program with a new analysis estimating its broader use pulled $6.5 billion in rebates away from the ...

Your recent story, 340B Pricing Program: Serving Vulnerable Patients or Enriching Hospitals?, contains several factual errors and contextual inaccuracies and leaves unchallenged specious statements by ...

The 100% woman-owned consulting firm partners with healthcare organizations to help them understand, implement, and optimize ...